• October 2012: ViThera scientific team published in Science Translational Medicine. The breakthrough data validate its approach for the delivery of elafin in treating gastrointestinal inflammation.
  • April 2012: ViThera awarded research grant from Johnson & Johnson's Corporate Office of Science and Technology (COSAT) to develop EnLact™ for Crohn's Disease and Ulcerative Colitis
  • September 2011: ViThera signs partnership deal with top-5 pharmaceutical company for development of inflammatory bowel disease drug on the basis of ViThera’s proprietary EnLact™ technology
  • September 2011: ViThera signs exclusive license for EnLact™ technology for the use in Inflammatory Bowel Disease and Irritable Bowel Syndrome with French INSERM (National Institute of Health and Medical Research) and INRA (National Institute of Agricultural Research)
  • August 2011: ViThera team files first patent on treatment and prevention of Salmonella infections in poultry using ViThera’s proprietary EnLact™ technology
  • April 2011: ViThera hires Laura Holberger, PhD, to head internal research and development into EnLact™ technology.
  • January 2011: ViThera collaborators publish key paper on Inflammatory bowel Disease.  VIThera collaborators Professor Nathalie Vergnolle (INSERM Toulouse, France) and Professor Jean-Michel Sallenave (Pasteur Institute Paris, France) published a key paper on Inflammatory Bowel Disease in the prestigious journal “Gastroenterology”.
  • January 2011: ViThera Pharmaceuticals Inc. founded to focus on development of novel therapeutics based on ViThera’s Engineered Lactic Acid Bacteria (EnLact™) platform. ViThera Pharmaceuticals is independent of ViThera Laboratories, which continues to offer custom laboratory services and lab space in Kendall Square.  ViThera Co-founders Johannes Fruehauf and Philippe Langella are joined by CFO (part time) Lisa Velardo and a seasoned advisory team containing Peter D. Parker (BioInnovation, Cequent, Ampersand Ventures), Peter Finn (Rubin & Rudman). IBD key opinion leader Dr. Balfour Sartor (UNC) joins ViThera’s Scientific Advisory Board.
  • October 2010: ViThera announced one of the "Final 26" startups of the MassChallenge Global Startup Competition and Accelerator. See news archive.
  • August 2010: ViThera Pharmaceuticals featured in Xconomy Boston. See news archive.
  • July 2010: ViThera Pharmaceuticals announced among the 110 finalists of the MassChallenge Global Startup Competition and Accelerator. See news archive.
  • May 2010: ViThera’s President, Johannes Fruehauf, will chair the Special Symposium on the Therapeutic use of Engineered Bacteria during the 110th General Meeting of ASM See news archive.
  • January 2010: ViThera Pharmaceuticals exits virtual mode and starts operations at One Kendall Square in Cambridge. See news archive.